Skip to main content
Cancer Science logoLink to Cancer Science
. 2009 Mar 9;100(6):1088–1091. doi: 10.1111/j.1349-7006.2009.01149.x

Personal use of hair dye and cancer risk in a prospective cohort of Chinese women

Julie Bloch Mendelsohn 1,, Qi‐Zhai Li 1,2, Bu‐Tian Ji 1, Xiao‐Ou Shu 3, Gong Yang 3, Hong‐Lan Li 4, Kyoung‐Mu Lee 1, Kai Yu 1, Nathaniel Rothman 1, Yu‐Tang Gao 4, Wei Zheng 3, Wong‐Ho Chow 1
PMCID: PMC2768318  NIHMSID: NIHMS140365  PMID: 19385970

Abstract

Although widely studied over the past 40 years, personal use of hair dye generally has not been associated with overall cancer risk. The association between hair dye use and risk of bladder and hematopoietic cancers has been less conclusive. Most hair dye studies have been case‐control studies conducted in Caucasian populations. We examined the relationship between personal hair dye use and cancer risk in a prospective cohort of 70 366 Chinese women. After an average of 7 years of follow up, 2437 women were newly diagnosed with cancer by 31 December 2005. Cox proportional hazard models were used to estimate relative risks (RR) and 95% confidence intervals (CI) of cancer risk associated with hair dye use, adjusting for potential confounding factors. Compared with women who reported no hair dye use, ever users had an overall cancer risk of 0.89 (95% CI 0.82, 0.97). No significant association was observed for several common cancers, including cancers of the breast (RR 0.93, 95% CI 0.78, 1.09), lung (RR 0.81, 95% CI 0.62, 1.09), stomach (RR 0.90, 95% CI 0.66, 1.21), and colorectum (RR 1.04, 95% CI 0.84, 1.28). We also found no significant association with most other cancers, including bladder cancer (RR 1.14, 95% CI 0.56, 2.35) and hematopoietic cancers overall (RR 0.89, 95% CI 0.59, 1.35) or their subtypes, including non‐Hodgkin lymphoma, multiple myeloma, and leukemia. We generally found no evidence of an association between personal use of hair dye and cancer risk, although our study is limited by small numbers for certain cancer types. (Cancer Sci 2009; 100: 1088–1091)


It is estimated that more than one‐third of women in the USA, Europe, and East Asia use hair dyes, with permanent hair dyes constituting the majority of the market share.( 1 , 2 ) Hair dyes have been known to contain aromatic amines, which were classified in 1993 by the International Agency for Research on Cancer (IARC) as probable bladder carcinogens in individuals with occupational exposure.( 2 , 3 , 4 ) However, both the 1993 and 2008 IARC working groups found that there was insufficient evidence to evaluate the carcinogenicity of personal use of hair dye.( 2 , 5 ) A recent comprehensive systematic review also concluded that the 25 studies conducted since the 1993 IARC decision do not provide sufficient evidence of a causal link between personal hair dye use and cancer.( 6 )

Although widely studied over the past 40 years, personal use of hair dye generally has not been associated with cancer risk overall, or with risk of common cancers such as lung, breast, and colorectal cancer.( 6 , 7 , 8 , 9 ) The association between hair dye use and risk of bladder and hematopoietic cancers has been less conclusive.( 6 , 7 , 10 , 11 , 12 , 13 , 14 ) Most studies that have reported positive associations have been case‐control studies conducted in Caucasian populations. These studies have found higher risks mainly with long‐term use of dark hair dye( 10 , 11 , 12 ) and hair dye use prior to 1980.( 15 , 16 , 17 )

To further examine the association between personal hair dye use and cancer risks, we analyzed data in a prospective, population‐based cohort study of Chinese women in Shanghai, where mostly dark hair dyes are used.

Materials and Methods

Study population.  The details of the Shanghai Women's Health Study have been published previously.( 18 ) A roster of 81 170 women aged 40–70 years was obtained from the resident offices in seven communities located in urban Shanghai, China. A total of 75 221 (92.7%) women completed baseline surveys between 1996 and 2000. Of the 5949 non‐participants, 2407 (3.0%) refused to be interviewed, 2073 (2.6%) were absent during the study period, and 1469 (1.8%) did not participate due to other reasons including health, hearing, and speaking problems. Of the respondents, we excluded 279 women who were found to be younger than age 40 years or older than age 70 years, and 1576 women who had a prevalent cancer at baseline. A total of 73 366 women remained for this analysis.

Data collection.  After obtaining informed consent, eligible individuals first completed a self‐administered questionnaire, which included hair dye exposure information. Trained interviewers conducted in‐person interviews to review the completeness and accuracy of the self‐administered questionnaire, complete an additional questionnaire, collect blood and urine specimens, and perform anthropometric measurements at baseline. Respondents were asked, ‘In the past 3 years, have you ever used hair dye?’ Women who gave an affirmative answer were then asked, ‘Over the past year, how many times did you use hair dye?’ and ‘How many years have you used hair dye?’ Other information obtained in the baseline questionnaire included demographic information, personal medical history, family medical history, reproductive history, occupational history, physical activity, diet, and lifestyle factors including active smoking, exposure to environmental tobacco smoke, and alcohol use.

Newly diagnosed cancer cases were ascertained through biennial surveys and linkage to the Shanghai Cancer Registry, which is legally mandated in Shanghai, China. Information on the date and hospital of diagnosis was collected. Medical charts and pathology slides were collected from the diagnostic hospital and reviewed by two study cancer pathologists to verify the diagnosis. In addition, death certificate data were collected from the Shanghai Vital Statistics Unit to identify causes of death for deceased participants. All incident cancer cases identified by 31 December 2005 were included in the present analysis.

Data analyses.  We estimated the association between hair dye use and risk for all cancers combined, as well as the risk for several specific cancers. Cox proportional hazards modeling was used to compute relative risks (RR) and 95% confidence intervals (CI). The end time of the observation in the model was set as the age at diagnosis for incident cancer subjects or age at death for deceased subjects. For those who did not encounter any of the events mentioned above, the end time was set as 31 December 2005. The left truncation of the model was set to the age at baseline interview. The survival model was stratified by birth cohort intervals (5‐year) to control for age and cohort effects. Other potential confounding variables, including education and smoking status, were controlled for in the final model. Further adjustment for family history of cancer, passive smoking, alcohol consumption, mean fruit and vegetable intake, mean energy expenditure, measured body mass index (BMI), number of live births, hormone replacement therapy use, menopausal status, age at menarche, income, and marital status did not result in any material changes of the observed associations (less than 10% change in the RR), and were therefore not included in the final models. Analyses were carried out in the statistical program R (version 2.3.1, Free Software Foundation, Inc. Boston, MA, USA). All tests were two‐sided, with a significance level of 0.05.

Results

In this population, 29 076 (39.63% of the cohort) reported ever using hair dye (Table 1). Hair dye use ranged from 1 to 52 years, with a median of 3 years and a mean of 3.8 years of use (excluding non‐users). Older women in the cohort tended to have a longer duration of use. The mean years of use in women aged 55–60, 60–65, and 65–70 years were 4.4, 5.2, and 6.1 years, respectively. Approximately 9% of all hair dye users in the cohort (2689 individuals) reported 10 or more years of hair dye use. Hair dye users had a median age of 51 years whereas non‐users had a median age of 49 years. Hair dye users were more likely to be post‐menopausal (51.70%) than non‐users (47.11%). Those who used hair dye were also more likely to have used hormone replacement therapy (2.76% of hair dye users vs 1.61% of non‐users). Compared to non‐users, hair dye users had higher income levels and were more highly educated. Hair dye users were as likely to have smoked and been exposed to passive smoke as non‐users, but were slightly more likely to have consumed alcohol. Fewer than 3% of all women in this cohort smoked or consumed alcohol regularly.

Table 1.

Characteristics of hair dye users and non‐users

Characteristic Users Non‐users
Number 29 076 44 290
Percentage of cohort (%) 39.63 60.37
Median age at interview (years)   51   49
Post menopausal (%) 51.70 47.11
Baseline measured BMI (median) 23.40 23.05
Ever smoker (%) 2.90 2.71
Ever drinker (%) 2.52   2.08
Ever exposed to passive smoke (%) 85.46 84.27
Married (%) 89.78 88.19
Ever used HRT (%) 2.76    1.61
Live births (%)
 0 2.96 3.51
 1 53.46 55.75
 2 25.18 18.42
 3 18.40 22.32
Educational level (%)
 Elementary school or less 16.99 24.28
 Middle school 37.23 37.14
 High school 29.52 26.89
 College 16.26 11.69
Income (%)
 <10 000 RMB 13.68 17.69
 10 000–<20 000 RMB 36.47 39.43
 20 000–<30 000 RMB 28.99 27.49
 ≥30 000 RMB 20.86 15.39
Mean vegetable intake (g/day) 302.52 295.11
Mean fruit intake (g/day) 285.71 260.73
Mean cumulative energy expenditure (kJ/min) 232.18 235.26

A total of 2437 incident cancer cases were identified during follow up through 31 December 2005. Compared with women who never used hair dye, ever users had a RR of 0.89 (95% CI 0.82, 0.97) for subsequent cancer (Table 2). We did not find an association between hair dye use and the risk of bladder cancer (RR 1.14, 95% CI 0.56, 2.35), hematopoietic cancers overall (RR 0.89, 95% CI 0.59, 1.35) or their subtypes, including non‐Hodgkin lymphoma (NHL), multiple myeloma, and leukemia. No significant association was observed for several common cancers, including cancers of the breast (RR 0.93, 95% CI 0.78, 1.09), lung (RR 0.81, 95% CI 0.62, 1.09), stomach (RR 0.90, 95% CI 0.66, 1.21), and colorectum (RR 1.04, 95% CI 0.84, 1.28). However, a significant inverse association was observed for thyroid cancer, with an estimated risk reduction of nearly 60% among hair dye users (RR 0.42, 95% CI 0.25, 0.69).

Table 2.

Relative risks * (RR) and 95% confidence intervals (CI) for the association of hair dye use (ever/never) with risk of major cancer sites in the Shanghai Women's Health Study

Cancer site No. non‐user cases No. user cases RR 95% CI
All cancer 1536 901 0.89 0.82, 0.97
Brain   24  15 0.96 0.49, 1.84
Thyroid   68  20 0.42 0.25, 0.69
Breast  358 234 0.93 0.78, 1.09
Lung  164  85 0.81 0.62, 1.09
Stomach  121  67 0.90 0.66, 1.21
Pancreatic   52  27 0.88 0.55, 1.41
Liver   67  33 0.83 0.54, 1.27
Colorectal  234 156 1.04 0.84, 1.28
Kidney   31  23 1.11 0.64, 1.92
Bladder   19  13 1.14 0.56, 2.35
Ovarian   62  38 0.89 0.59, 1.35
Uterine   71  54 1.10 0.77, 1.58
Hematopoietic   64  35 0.89 0.59, 1.35
 Non‐Hodgkin lymphoma   31  20 1.09 0.61, 1.92
 Multiple myeloma   12   6 0.84 0.31, 2.27
 Leukemia   20   9 0.68 0.31, 1.51
*

RR were derived using Cox proportional hazards models, adjusted for age, education, and smoking duration in pack/years. The average number of person years was 7.31.

The number of non‐user controls was 42 739.

The number of user controls was 28 166.

We found no consistent pattern between cancer risk and years of hair dye use for all cancers combined, or for any individual cancers (Table 3). An excess risk of borderline significance was observed for ovarian cancer among those who used hair dye for 5–9 years (RR 1.67, 95% CI 0.87, 3.19), and for bladder cancer among hair dye users of 3–4 years (RR 2.16, 95% CI 0.89, 5.22). For thyroid cancer, a 50–60% reduction in risk was associated with hair dye use across all duration of use categories, with the associations reaching significance for short‐term users.

Table 3.

Relative risks * (RR) and 95% confidence intervals (CI) for duration of hair dye use and risk of major cancer sites in the Shanghai Women's Health Study

Cancer site No. non‐user cases 1–2 years 3–4 years 5–9 years ≥10 years
No. user cases RR 95% CI No. user cases RR 95% CI No. user cases RR 95% CI No. user cases RR 95% CI
All cancer 1536 386 0.89 0.79, 0.99 237 0.81 0.71, 0.93 161 0.96 0.82, 1.14 116 0.90 0.74, 1.09
Brain   24   7 1.03 0.44, 2.42   2 0.45 0.11, 1.95   3 1.16 0.35, 3.92   3 1.49 0.44, 5.02
Thyroid   68  10 0.45 0.23, 0.87   5 0.35 0.14, 0.87   3 0.40 0.13, 1.28   2 0.44 0.11, 1.83
Breast  358 105 0.90 0.72, 1.12  66 0.87 0.66, 1.13  37 0.91 0.65, 1.29  26 1.00 0.67, 1.50
Lung  164  30 0.70 0.47, 1.04  21 0.70 0.44, 1.11  14 0.78 0.45, 1.35  20 1.29 0.81, 2.06
Stomach  121  29 0.94 0.62, 1.41  16 0.76 0.45, 1.29  17 1.35 0.81, 2.25   5 0.47 0.19, 1.15
Pancreatic   53  14 1.17 0.64, 2.12   6 0.70 0.30, 1.64   3 0.54 0.17, 1.74   3 0.55 0.17, 1.78
Liver   67  14 0.85 0.47, 1.52  12 1.10 0.59, 2.05   5 0.76 0.31, 1.91   2 0.35 0.09, 1.43
Colorectal  234  66 1.09 0.83, 1.44  42 1.00 0.71, 1.39  30 1.14 0.78, 1.68  18 0.79 0.49, 1.28
Kidney   31  13 1.46 0.76, 2.81   5 0.82 0.32, 2.13   1 0.29 0.04, 2.13   4 1.50 0.52, 4.32
Bladder   19   3 0.59 0.17, 2.00   7 2.16 0.89, 5.22   2 1.14 0.26, 4.95   1 0.75 0.10, 5.66
Ovarian   62  10 0.51 0.26, 0.99  11 0.87 0.46, 1.66  11 1.67 0.87, 3.19   6 1.44 0.61, 3.38
Uterine   71  26 1.18 0.75, 1.85  16 1.08 0.62, 1.87   7 0.88 0.40, 1.92   5 0.98 0.39, 2.44
Hematopoietic   64  12 0.70 0.37, 1.30  13 1.18 0.65, 2.16   7 1.12 0.51, 2.46   3 0.59 0.18, 1.90
 Non‐Hodgkin lymphoma   31   8 1.03 0.47, 2.26   7 1.36 0.59, 3.13   3 0.99 0.30, 3.28   2 0.74 0.17, 3.11
 Multiple myeloma   12   2 0.69 0.15, 3.14   2 1.03 0.23, 4.65   2 1.63 0.36, 7.37   0
 Leukemia   20   2 0.31 0.07, 1.31   4 1.05 0.36, 3.12   2 1.05 0.24, 4.56   1 0.89 0.12, 6.76
*

RR were derived using Cox proportional hazards models, adjusting for age, education, and smoking duration in pack/years. The average number of person years was 7.31.

We further examined cancer risks among 486 women who reported using hair dye for 20 or more years. After adjusting for age and education, the RR for all cancers combined in this group was 1.00 (95% CI 0.67, 1.49). A significant excess risk among hair dye users was found for ovarian cancer (RR 5.95, 95% CI 2.13–16.68; N = 4 cases). No significant association was observed for other cancers (data not shown).

We carried out additional sub‐analyses for selected cancers. For lung cancer, we stratified results by smoking status but found no significant association between hair dye use and cancer in either smokers or non‐smokers. When we stratified by menopausal status, we found no association between breast or ovarian cancer and hair dye use in either pre‐ or post‐menopausal women.

We carried out additional tests to determine whether frequent hair dye users (>12 times per year) had a different RR of cancer than less‐frequent users. The difference in RR between these two groups was very slight. Finally, we excluded cases diagnosed during the first 2 years of follow up and found no material difference in the overall risk of cancer.

Discussion

In this large prospective study, we generally found no association between hair dye use and risk of overall cancer. We found no evidence that hair dye use increases the risk of bladder cancer or hematopoietic cancer, the two malignancies most frequently linked with hair dye use in the literature. A significant increased risk for ovarian cancer was associated with long‐term hair dye use (≥20 years), but the result was based on a very small number of cases. We have no explanation for the significant inverse association observed for thyroid cancer, but chance variation or failure to adjust for confounding factors not measured in our study are possible explanations. Although the lack of a dose response in risk with duration of hair dye use tends to argue against a causal relationship, further assessment of the link between hair dye use and thyroid cancer risk may be warranted.

Our findings are consistent with previous cohort and case‐control studies that have generally reported no association or a non‐significant inverse association between hair dye use and cancer.( 8 , 9 , 10 , 11 , 19 , 20 ) The most recent systematic review concluded that the 25 studies conducted since the 1993 IARC review do not provide sufficient evidence of a causal link between hair dye and cancer.( 6 ) The CPS‐II study, which was the largest cohort to examine this association, initially reported a statistically significant inverse association almost identical to our findings;( 11 ) however, no association was observed after additional follow up.( 10 )

Despite several studies that have reported null associations;( 8 , 19 , 21 , 22 ) hair dye has continued to be a concern because a number of case‐control studies and a meta‐analysis have found links between personal hair dye use and bladder cancer.( 23 , 24 , 25 ) Hair dye use has also been suggested as a risk factor for NHL,( 9 , 10 , 12 , 17 ) leukemia,( 26 , 27 , 28 ) multiple myeloma,( 12 , 29 ) and myelodysplasia,( 30 ) although several other studies found no association with hematopoietic cancers.( 15 , 20 , 31 , 32 ) Statistically significant increases in risk have been found in case‐control studies of hair dye use and glioma,( 33 , 34 ) ovarian cancer,( 35 ) and cancer of the salivary gland.( 36 ) A recent meta‐analysis concluded that there was no strong evidence of an association between hair dye use and risk of breast, bladder, and hematopoietic malignancies; however, this analysis did not consider specific exposure measurements such as duration, color, and frequency of use.( 7 )

Long‐term use of dark dye has been associated with increased cancer risk in a few studies.( 10 , 11 ) However, these studies have had limited power due to the low prevalence of long‐term exposure to dark hair dyes.( 13 , 14 ) Most studies have been conducted in Caucasian women who use a range of light and dark colors, and where users of black dye have generally accounted for less than 1% of study participants.( 11 , 33 , 34 ) Two studies in a Japanese population reported associations between hair dye use and myelodysplastic syndrome.( 30 , 37 ) Although we did not collect data on hair dye color, it is likely that our study population of mostly middle‐aged and elderly Chinese women used primarily dark or black dye. However, we were unable to obtain data published in the scientific literature documenting the use of hair dye by type in China. To the extent that this population used primarily dark hair dye, a type that has been most commonly linked to cancer risk, our observation of no association even among long‐term users suggests that personal hair dye use is probably not a strong cancer risk factor.

Recently, a few studies have found associations between hair dye use and NHL and bladder cancer in subsets of the study population, such as individuals who are N‐acetyltransferase 2 slow acetylators,( 25 ) N‐acetyltransferase 2 rapid acetylators,( 16 ) and individuals who used hair dyes prior to 1980.( 15 , 16 , 17 ) Our analysis did not evaluate associations in susceptible subgroups of the population, although overall we found no association among hair dye users of 20 or more years. Whether hair dye use increases cancer risk in certain susceptible subgroups and whether particular chemical components of hair dyes pose more risk than others may warrant further investigation.

Our study was limited by the brief nature of the questions on hair dye use in the baseline questionnaire. No questions were asked about the color or type of hair dye used (e.g. permanent, semipermanent). It is also possible that our data underestimates exposure to hair dye because women who had not used hair dye in the 3 years prior to interview were classified as non‐users, even if they used hair dye previously. This misclassification is likely non‐differential and may tend to bias the risk estimates towards the null. Despite the large number of hair dye users in our cohort, the number of cases of specific cancers was small, thus limiting the possibility for a more detailed analysis. The small numbers also produced unstable risk estimates for some less common cancers.

In conclusion, we found no evidence of an association between personal use of hair dye and overall cancer risk in this large prospective study in Chinese women. Further studies are warranted to clarify whether personal use of hair dye increases the risk of specific cancers in susceptible individuals.

Acknowledgments

This work was supported by National Institutes of Health (NIH) research grant R01 CA70867 and by the Intramural Research Program of NIH (Division of Cancer Epidemiology and Genetics, National Cancer Institute). The authors wish to thank Sheila H. Zahm for her helpful advice on this manuscript. The authors express their appreciation to the Shanghai residents who participated in the study and thank the research staff of the Shanghai Women's Health Study for their dedication and contributions to the study.

References

  • 1. La Vecchia C, Tavani A. Hair dyes and lymphoid neoplasms: an update. Eur J Cancer Prev 2002; 11: 409–12. [DOI] [PubMed] [Google Scholar]
  • 2. IARC . Working Group on the evaluation of carcinogenic risks to humans: occupational exposures of hairdressers and barbers and personal use of hair colourants; some hair dyes, cosmetic colourants, industrial dyestuffs and aromatic amines. October 1992, France: Lyon, 6–13. IARC Monogr Eval Carcinog Risks Hum 1993; 57: 7–398. [PMC free article] [PubMed] [Google Scholar]
  • 3. Turesky RJ, Freeman JP, Holland RD et al . Identification of aminobiphenyl derivatives in commercial hair dyes. Chem Res Toxicol 2003; 16: 1162–73. [DOI] [PubMed] [Google Scholar]
  • 4. Choudhary G. Human health perspectives on environmental exposure to benzidine: a review. Chemosphere 1996; 32: 267–91. [DOI] [PubMed] [Google Scholar]
  • 5. Baan R, Straif K, Grosse Y et al . Carcinogenicity of some aromatic amines, organic dyes, and related exposures. Lancet Oncol 2008; 9: 322–3. [DOI] [PubMed] [Google Scholar]
  • 6. Rollison DE, Helzlsouer KJ, Pinney SM. Personal hair dye use and cancer: a systematic literature review and evaluation of exposure assessment in studies published since 1992. J Toxicol Environ Health B Crit Rev 2006; 9: 413–39. [DOI] [PubMed] [Google Scholar]
  • 7. Takkouche B, Etminan M, Montes‐Martinez A. Personal use of hair dyes and risk of cancer: a meta‐analysis. JAMA 2005; 293: 2516–25. [DOI] [PubMed] [Google Scholar]
  • 8. Hartge P, Hoover R, Altman R et al . Use of hair dyes and risk of bladder cancer. Cancer Res 1982; 42: 4784–7. [PubMed] [Google Scholar]
  • 9. Zheng T, Holford TR, Mayne ST et al . Use of hair colouring products and breast cancer risk: a case‐control study in Connecticut. Eur J Cancer 2002; 38: 1647–52. [DOI] [PubMed] [Google Scholar]
  • 10. Altekruse SF, Henley SJ, Thun MJ. Deaths from hematopoietic and other cancers in relation to permanent hair dye use in a large prospective study (United States). Cancer Causes Control 1999; 10: 617–25. [DOI] [PubMed] [Google Scholar]
  • 11. Thun MJ, Altekruse SF, Namboodiri MM, Calle EE, Myers DG, Heath CW Jr. Hair dye use and risk of fatal cancers in US women. J Natl Cancer Inst 1994; 86: 210–15. [DOI] [PubMed] [Google Scholar]
  • 12. Zahm SH, Weisenburger DD, Babbitt PA, Saal RC, Vaught JB, Blair A. Use of hair coloring products and the risk of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Am J Public Health 1992; 82: 990–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Correa A, Jackson L, Mohan A, Perry H, Helzlsouer K. Use of hair dyes, hematopoietic neoplasms, and lymphomas: a literature review. II. Lymphomas and multiple myeloma. Cancer Invest 2000; 18: 467–79. [DOI] [PubMed] [Google Scholar]
  • 14. Correa A, Mohan A, Jackson L, Perry H, Helzlsouer K. Use of hair dyes, hematopoietic neoplasms, and lymphomas: a literature review. I. Leukemias and myelodysplastic syndromes. Cancer Invest 2000; 18: 366–80. [DOI] [PubMed] [Google Scholar]
  • 15. De Sanjose S, Benavente Y, Nieters A et al . Association between personal use of hair dyes and lymphoid neoplasms in Europe. Am J Epidemiol 2006; 164: 47–55. [DOI] [PubMed] [Google Scholar]
  • 16. Morton LM, Bernstein L, Wang SS et al . Hair dye use, genetic variation in N‐acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non‐Hodgkin lymphoma. Carcinogenesis 2007; 28: 1759–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Zhang Y, Sanjose SD, Bracci PM et al . Personal use of hair dye and the risk of certain subtypes of non‐Hodgkin lymphoma. Am J Epidemiol 2008; 167: 1321–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Zheng W, Chow WH, Yang G et al . The Shanghai Women's Health Study: rationale, study design, and baseline characteristics. Am J Epidemiol 2005; 162: 1123–31. [DOI] [PubMed] [Google Scholar]
  • 19. Lin J, Dinney CP, Grossman HB, Wu X. Personal permanent hair dye use is not associated with bladder cancer risk: evidence from a case‐control study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1746–9. [DOI] [PubMed] [Google Scholar]
  • 20. Grodstein F, Hennekens CH, Colditz GA, Hunter DJ, Stampfer MJ. A prospective study of permanent hair dye use and hematopoietic cancer. J Natl Cancer Inst 1994; 86: 1466–70. [DOI] [PubMed] [Google Scholar]
  • 21. Kogevinas M, Fernandez F, Garcia‐Closas M et al . Hair dye use is not associated with risk for bladder cancer: evidence from a case‐control study in Spain. Eur J Cancer 2006; 42: 1448–54. [DOI] [PubMed] [Google Scholar]
  • 22. Kelsh MA, Alexander DD, Kalmes RM, Buffler PA. Personal use of hair dyes and risk of bladder cancer: a meta‐analysis of epidemiologic data. Cancer Causes Control 2008; 19: 549–58. [DOI] [PubMed] [Google Scholar]
  • 23. Huncharek M, Kupelnick B. Personal use of hair dyes and the risk of bladder cancer: results of a meta‐analysis. Public Health Rep 2005; 120: 31–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Andrew AS, Schned AR, Heaney JA, Karagas MR. Bladder cancer risk and personal hair dye use. Int J Cancer 2004; 109: 581–6. [DOI] [PubMed] [Google Scholar]
  • 25. Gago‐Dominguez M, Bell DA, Watson MA et al . Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N‐acetyltransferases 1 and 2. Carcinogenesis 2003; 24: 483–9. [DOI] [PubMed] [Google Scholar]
  • 26. Cantor KP, Blair A, Everett G et al . Hair dye use and risk of leukemia and lymphoma. Am J Public Health 1988; 78: 570–1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Rauscher GH, Shore D, Sandler DP. Hair dye use and risk of adult acute leukemia. Am J Epidemiol 2004; 160: 19–25. [DOI] [PubMed] [Google Scholar]
  • 28. Miligi L, Costantini AS, Benvenuti A et al . Personal use of hair dyes and hematolymphopoietic malignancies. Arch Environ Occup Health 2005; 60: 249–56. [DOI] [PubMed] [Google Scholar]
  • 29. Brown LM, Everett GD, Burmeister LF, Blair A. Hair dye use and multiple myeloma in white men. Am J Public Health 1992; 82: 1673–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Nagata C, Shimizu H, Hirashima K et al . Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. Leuk Res 1999; 23: 57–62. [DOI] [PubMed] [Google Scholar]
  • 31. Benavente Y, Garcia N, Domingo‐Domenech E et al . Regular use of hair dyes and risk of lymphoma in Spain. Int J Epidemiol 2005; 34: 1118–22. [DOI] [PubMed] [Google Scholar]
  • 32. Koutros S, Baris D, Bell E et al . Use of hair colouring products and risk of multiple myeloma among US women. Occup Environ Med 2009; 66: 68–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Bluhm EC, Zahm SH, Fine HA et al . Personal hair dye use and risks of glioma, meningioma, and acoustic neuroma among adults. Am J Epidemiol 2007; 165: 63–71. [DOI] [PubMed] [Google Scholar]
  • 34. Heineman EF, Ward MH, McComb RD, Weisenburger DD, Zahm SH. Hair dyes and risk of glioma among Nebraska women. Cancer Causes Control 2005; 16: 857–64. [DOI] [PubMed] [Google Scholar]
  • 35. Tzonou A, Polychronopoulou A, Hsieh CC, Rebelakos A, Karakatsani A, Trichopoulos D. Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. Int J Cancer 1993; 55: 408–10. [DOI] [PubMed] [Google Scholar]
  • 36. Spitz MR, Fueger JJ, Goepfert H, Newell GR. Salivary gland cancer. A case‐control investigation of risk factors. Arch Otolaryngol Head Neck Surg 1990; 116: 1163–6. [DOI] [PubMed] [Google Scholar]
  • 37. Ido M, Nagata C, Kawakami N et al . A case‐control study of myelodysplastic syndromes among Japanese men and women. Leuk Res 1996; 20: 727–31. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES